Lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. New findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types.
source https://www.sciencedaily.com/releases/2021/07/210706102047.htm
Wednesday, 7 July 2021
Previous Post
Game-changing zeolite catalysts synthesized
Related Posts
Citizens versus the internet: Confronting digital challenges with cognitive toolsResearchers recommend ways that psychological and behavioral sciences … Read More
Ecosystem dynamics: Topological phases in biological systemsPhysicists have shown that topological phases could exist in biology, … Read More
Scientists complete yearlong pulsar timing study after reviving dormant radio telescopesWhile the scientific community grapples with the loss of the Arecibo r… Read More
Melody of an Alpine summit falling apartThe summit of the 2592 meters high Hochvogel is sliced by dangerous fr… Read More
CRISPR helps researchers uncover how corals adjust to warming oceansThe CRISPR/Cas9 genome editing system can help scientists understand, … Read More
New phase for synthetic aperture microscopyAlthough SAM is undoubtedly a promising approach, current implementati… Read More
0 comments: